| Name | Title | Contact Details |
|---|---|---|
Sean Shapiro |
Vice President of Sales | Profile |
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.
Ceres Inc is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Wake Researchs network of high-quality research sites and millions of patients is built on decades of experience meeting the needs of sponsors & CROs.
vTv Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.